{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T02:05:40Z","timestamp":1771553140997,"version":"3.50.1"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate peficitinib efficacy and safety in Asian patients with rheumatoid arthritis (RA), stratified by age (\u226520\u2013&amp;lt;50, \u226550\u2013&amp;lt;65, and \u226565\u2009years).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Efficacy data from two Phase 3 studies were analysed. Safety data from one Phase 2, two Phase 3, and one open-label extension study were pooled. Incidence rates per 100 patient-years of adverse events of special interest were calculated, and Cox proportional hazard analysis was conducted.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>1052 patients received peficitinib for 2\u2009years (median). Peficitinib demonstrated efficacy improvements versus placebo across all age categories. Incidence rates (95% confidence interval) per 100 patient-years for \u226520\u2013&amp;lt;50, \u226550\u2013&amp;lt;65, and \u226565\u2009years were 0.8 (0.4, 1.9), 2.6 (1.8, 3.7), and 4.7 (3.1, 7.0) for serious infections and 3.7 (2.5, 5.4), 6.4 (5.0, 8.2), and 11.2 (8.5, 14.7) for herpes zoster\u2013related disease, respectively. Twenty patients reported malignancies in pooled Phase 2\/3 studies. Incidences of serious infections and herpes zoster\u2013related disease increased significantly with age, but there was no association with baseline estimated glomerular filtration rate.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Peficitinib was efficacious in adult Asian RA patients of all ages. Age, but not estimated glomerular filtration rate, was associated with serious infections and herpes zoster\u2013related disease, demonstrating the importance of an appropriate RA treatment strategy in older patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roab058","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T13:21:23Z","timestamp":1634736083000},"page":"696-707","source":"Crossref","is-referenced-by-count":7,"title":["Impact of age on the efficacy and safety of peficitinib (ASP015K) for the treatment of rheumatoid arthritis"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"first","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health , Japan, Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1111-8218","authenticated-orcid":false,"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1710-4319","authenticated-orcid":false,"given":"Daisuke","family":"Kato","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Musashi","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Miyatake","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,9,3]]},"reference":[{"key":"2022070111370213900_R1","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/art.10897","article-title":"Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification","volume":"48","author":"Rasch","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2022070111370213900_R2","article-title":"Statistical Handbook of Japan [Internet]","author":"Statisitics Bureau","year":"2015"},{"key":"2022070111370213900_R3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/1756-185X.12998","article-title":"The age at onset of rheumatoid arthritis is increasing in Japan: a nationwide database study","volume":"20","author":"Kato","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"2022070111370213900_R4","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102528","article-title":"Rheumatoid arthritis in the elderly: characteristics and treatment considerations","volume":"19","author":"Serhal","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2022070111370213900_R5","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/1756-185X.13974","article-title":"Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan","volume":"23","author":"Nakajima","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"2022070111370213900_R6","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/14397595.2019.1682776","article-title":"Epidemiological characteristics of rheumatoid arthritis in Japan: prevalence estimates using a nationwide population-based questionnaire survey","volume":"30","author":"Kojima","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2022070111370213900_R7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.ackd.2015.08.004","article-title":"Structural and functional changes with the aging kidney","volume":"23","author":"Denic","year":"2016","journal-title":"Adv Chronic Kidney Dis"},{"key":"2022070111370213900_R8","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3109\/03009742.2016.1143966","article-title":"Renal diseases in patients with rheumatoid arthritis","volume":"45","author":"Koivuniemi","year":"2016","journal-title":"Scand J Rheumatol"},{"key":"2022070111370213900_R9","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/j.ajkd.2013.08.010","article-title":"Development of reduced kidney function in rheumatoid arthritis","volume":"63","author":"Hickson","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2022070111370213900_R10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0160225","article-title":"Inflammation as a risk of developing chronic kidney disease in rheumatoid arthritis","volume":"11","author":"Kochi","year":"2016","journal-title":"PLoS One"},{"key":"2022070111370213900_R11","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1007\/s10067-017-3804-5","article-title":"Prevalence of and factors associated with renal dysfunction in rheumatoid arthritis patients: a cross-sectional study in community hospitals","volume":"36","author":"Mori","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2022070111370213900_R12","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022070111370213900_R13","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/1756-185X.13513","article-title":"2018 update of the APLAR recommendations for treatment of rheumatoid arthritis","volume":"22","author":"Lau","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"2022070111370213900_R14","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2016.175","article-title":"Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers","volume":"12","author":"Brown","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2022070111370213900_R15","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00296-020-04547-y","article-title":"Methotrexate-related toxicity in patients with rheumatoid arthritis and renal dysfunction","volume":"40","author":"Lee","year":"2020","journal-title":"Rheumatol Int"},{"key":"2022070111370213900_R16","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1136\/annrheumdis-2019-215163","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)","volume":"78","author":"Tanaka","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2022070111370213900_R17","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/annrheumdis-2019-215164","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2022070111370213900_R18","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/14656566.2020.1739649","article-title":"Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials","volume":"21","author":"Tanaka","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"2022070111370213900_R19","article-title":"Drug Details: 100 mg Smyraf (Peficitinib Hydrobromide) [Internet]","author":"Astellas Pharma Taiwan, Inc","year":"2020"},{"key":"2022070111370213900_R20","article-title":"Drug Details: 50 mg Smyraf (Peficitinib Hydrobromide) [Internet]","author":"Astellas Pharma Taiwan, Inc","year":"2020"},{"key":"2022070111370213900_R21","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1080\/14397595.2020.1836789","article-title":"A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years","volume":"31","author":"Takeuchi","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2022070111370213900_R22","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1002\/art.38779","article-title":"Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis","volume":"66","author":"Cohen","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2022070111370213900_R23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/rheumatology\/key075.443","article-title":"Safety summary results of baricitinib focusing on serious infections events and preselected comorbidities","volume":"57","author":"Combe","year":"2018","journal-title":"Rheumatology"},{"key":"2022070111370213900_R24","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s00296-010-1524-0","article-title":"Incidence of malignancy in Japanese patients with rheumatoid arthritis","volume":"31","author":"Yamada","year":"2011","journal-title":"Rheumatol Int"},{"key":"2022070111370213900_R25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amepre.2013.10.029","article-title":"Age and cancer risk: a potentially modifiable relationship","volume":"46","author":"White","year":"2014","journal-title":"Am J Prev Med"},{"key":"2022070111370213900_R26","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/annrheumdis-2015-208279","article-title":"Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study","volume":"75","author":"Takeuchi","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022070111370213900_R27","article-title":"Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan","volume":"22","author":"Takeuchi","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2022070111370213900_R28","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med United States"},{"key":"2022070111370213900_R29","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40744-021-00280-5","article-title":"Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: final results (32 months of mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan","volume":"8","author":"Takeuchi","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2022070111370213900_R30","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/acr.21649","article-title":"Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice","volume":"64","author":"Anderson","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2022070111370213900_R31","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s40266-020-00801-x","article-title":"Safety and effectiveness of biologic disease-modifying antirheumatic drugs in older patients with rheumatoid arthritis: a prospective cohort study","volume":"37","author":"Freitas","year":"2020","journal-title":"Drugs Aging"},{"key":"2022070111370213900_R32","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.3899\/jrheum.160012","article-title":"Safety of biologic agents in elderly patients with rheumatoid arthritis","volume":"43","author":"Murota","year":"2016","journal-title":"J Rheumatol"},{"key":"2022070111370213900_R33","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1080\/14397595.2018.1525019","article-title":"Clinical effectiveness and long-term retention of abatacept in elderly rheumatoid arthritis patients: results from a multicenter registry system","volume":"29","author":"Takahashi","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2022070111370213900_R34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/rmdopen-2017-000498","article-title":"Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme","volume":"3","author":"Yamanaka","year":"2017","journal-title":"RMD Open"},{"key":"2022070111370213900_R35","doi-asserted-by":"crossref","DOI":"10.1186\/s12877-017-0420-9","article-title":"The temporal impact of aging on the burden of herpes zoster","volume":"17","author":"Varghese","year":"2017","journal-title":"BMC Geriatr"},{"key":"2022070111370213900_R36","article-title":"Report on the Deliberation Results: Olumiant Tablets 2 mg, 4 mg [Internet]","author":"Ministry of Health Labour and Welfare Japan","year":"2017"},{"key":"2022070111370213900_R37","first-page":"390","article-title":"Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis","volume":"35","author":"Curtis","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2022070111370213900_R38","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40261-020-00910-w","article-title":"Pharmacokinetics, pharmacodynamics, and safety of peficitinib (ASP015K) in healthy male Caucasian and Japanese subjects","volume":"40","author":"Shibata","year":"2020","journal-title":"Clin Drug Investig"},{"key":"2022070111370213900_R39","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1111\/bcp.14605","article-title":"Population pharmacokinetic analysis of peficitinib in patients with rheumatoid arthritis","volume":"87","author":"Toyoshima","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2022070111370213900_R40","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40261-019-00873-7","article-title":"Pharmacokinetics and safety of a single oral dose of peficitinib (ASP015K) in Japanese subjects with normal and impaired renal function","volume":"40","author":"Miyatake","year":"2020","journal-title":"Clin Drug Investig"},{"key":"2022070111370213900_R41","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/jcph.178","article-title":"Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease","volume":"54","author":"Krishnaswami","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"2022070111370213900_R42","article-title":"Xeljanz Tablets 5 mg report [Internet]","author":"Ministry of Health Labour and Welfare Japan","year":"2013"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roab058\/42773446\/roab058.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/4\/696\/44366397\/roab058.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/4\/696\/44366397\/roab058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T11:38:55Z","timestamp":1656675535000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/32\/4\/696\/6363741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,3]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,9,3]]},"published-print":{"date-parts":[[2022,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roab058","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2021,9,3]]}}}